Justin Doan

5.8k total citations
27 papers, 960 citations indexed

About

Justin Doan is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Justin Doan has authored 27 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Economics and Econometrics and 11 papers in Oncology. Recurrent topics in Justin Doan's work include Renal cell carcinoma treatment (13 papers), Economic and Financial Impacts of Cancer (13 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Justin Doan is often cited by papers focused on Renal cell carcinoma treatment (13 papers), Economic and Financial Impacts of Cancer (13 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Justin Doan collaborates with scholars based in United States, United Kingdom and Germany. Justin Doan's co-authors include Robert W. Baran, S. Bolge, Hema Kannan, Robert J. Motzer, David Cella, Paul Nathan, Viktor Grünwald, Saby George, Bernard Escudier and Hans J. Hammers and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Justin Doan

25 papers receiving 942 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Justin Doan United States 12 471 450 168 155 140 27 960
Angela Wu United States 18 149 0.3× 523 1.2× 252 1.5× 126 0.8× 53 0.4× 45 1.0k
Joseph F. O’Donnell United States 13 199 0.4× 134 0.3× 88 0.5× 65 0.4× 69 0.5× 29 975
Kerry Rowe United States 18 592 1.3× 345 0.8× 119 0.7× 66 0.4× 12 0.1× 57 1.1k
Alyson Norman United Kingdom 17 935 2.0× 410 0.9× 207 1.2× 162 1.0× 12 0.1× 52 1.7k
Ute‐Susann Albert Germany 20 689 1.5× 171 0.4× 64 0.4× 381 2.5× 12 0.1× 55 1.5k
Damien Urban Israel 19 758 1.6× 492 1.1× 194 1.2× 146 0.9× 17 0.1× 59 1.2k
Albert M. Bernath United States 18 501 1.1× 277 0.6× 209 1.2× 169 1.1× 20 0.1× 39 1.1k
J. Bernhard Switzerland 18 510 1.1× 451 1.0× 50 0.3× 148 1.0× 9 0.1× 36 1.1k
Tracy Slanger Germany 17 364 0.8× 279 0.6× 93 0.6× 87 0.6× 34 0.2× 22 1.2k
Ravinder Dhawan United States 17 257 0.5× 146 0.3× 186 1.1× 26 0.2× 42 0.3× 42 1.3k

Countries citing papers authored by Justin Doan

Since Specialization
Citations

This map shows the geographic impact of Justin Doan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin Doan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin Doan more than expected).

Fields of papers citing papers by Justin Doan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin Doan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin Doan. The network helps show where Justin Doan may publish in the future.

Co-authorship network of co-authors of Justin Doan

This figure shows the co-authorship network connecting the top 25 collaborators of Justin Doan. A scholar is included among the top collaborators of Justin Doan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin Doan. Justin Doan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oikonomidou, Olga, Mark Beresford, Rohan Parikh, et al.. (2025). Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2− advanced breast cancer in Europe. Breast Cancer Research and Treatment. 213(3). 299–312.
2.
Samjoo, Imtiaz A., Alexandra Hall, Mary Lou Smith, et al.. (2024). A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. Journal of Comparative Effectiveness Research. 13(10). e240111–e240111. 6 indexed citations
3.
Hollenbeak, Christopher S., Élise Schaefer, Justin Doan, & Jay D. Raman. (2019). Determinants of treatment in patients with stage IV renal cell carcinoma. BMC Urology. 19(1). 123–123. 6 indexed citations
4.
5.
Deniz, Baris, Shuo Yang, Arman Altincatal, et al.. (2019). Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS ONE. 14(8). e0215761–e0215761. 15 indexed citations
6.
Shah, Ruchit, Marc Botteman, Caitlyn T. Solem, et al.. (2019). A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). Clinical Genitourinary Cancer. 17(5). 356–365.e1. 11 indexed citations
7.
Cella, David, Viktor Grünwald, Bernard Escudier, et al.. (2019). Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. The Lancet Oncology. 20(2). 297–310. 186 indexed citations
8.
Yang, Shuo, et al.. (2018). Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States. Experimental Hematology and Oncology. 7(1). 4–4. 22 indexed citations
9.
10.
Cella, David, Bernard Escudier, Hans J. Hammers, et al.. (2018). Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial.. Journal of Clinical Oncology. 36(15_suppl). 3073–3073. 3 indexed citations
11.
Deniz, Baris, Arman Altincatal, Sumati Rao, et al.. (2018). Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS ONE. 13(8). e0203406–e0203406. 1 indexed citations
12.
Escudier, Bernard, Robert J. Motzer, Padmanee Sharma, et al.. (2017). Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology. 72(3). 368–376. 176 indexed citations
13.
Shafrin, Jason, et al.. (2017). The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma. Cancer Management and Research. Volume 9. 731–739. 9 indexed citations
14.
Santi, Irene, et al.. (2017). Is RECIST-defined progression free-survival a meaningful endpoint in the era of immunotherapy?. Journal of Clinical Oncology. 35(6_suppl). 488–488. 7 indexed citations
15.
Hollenbeak, Christopher S., Élise Schaefer, Justin Doan, & Jay D. Raman. (2017). Determinants of treatment in patients with stage IV renal cell carcinoma.. Journal of Clinical Oncology. 35(6_suppl). 486–486.
16.
Cella, David, Viktor Grünwald, Paul Nathan, et al.. (2016). Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. The Lancet Oncology. 17(7). 994–1003. 156 indexed citations
17.
Griffiths, Robert I., Deepa Lalla, Robert J. Herbert, et al.. (2011). Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Cancer Investigation. 29(9). 573–584. 16 indexed citations
18.
Beyer, A, Sheryl L. Szeinbach, Enrique Seoane‐Vazquez, et al.. (2010). Assessing the reliability and validity of a newly developed insomnia treatment satisfaction questionnaire (ITSAT-Q). Sleep Medicine. 11(8). 766–771. 7 indexed citations
19.
Kleinman, Nathan L., Richard A. Brook, Justin Doan, Arthur K. Melkonian, & Robert W. Baran. (2009). Health Benefit Costs and Absenteeism Due to Insomnia From the Employer’s Perspective. The Journal of Clinical Psychiatry. 70(8). 1098–1104. 49 indexed citations
20.
Bolge, S., Justin Doan, Hema Kannan, & Robert W. Baran. (2009). Association of insomnia with quality of life, work productivity, and activity impairment. Quality of Life Research. 18(4). 415–422. 205 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Wu Breakdown of academic impact, for papers by Joseph F. O’Donnell Breakdown of academic impact, for papers by Kerry Rowe Breakdown of academic impact, for papers by Alyson Norman Breakdown of academic impact, for papers by Ute‐Susann Albert Breakdown of academic impact, for papers by Damien Urban Breakdown of academic impact, for papers by Albert M. Bernath Breakdown of academic impact, for papers by J. Bernhard Breakdown of academic impact, for papers by Tracy Slanger Breakdown of academic impact, for papers by Ravinder Dhawan
Rankless by CCL
2026